#amgen inc.

[customdesignnnn]

The Dow Jones falls 330 points as the Fed plans to reduce its balance sheet and considers bigger rate hikes

The Dow Jones falls 330 points as the Fed plans to reduce its balance sheet and considers bigger rate hikes

Stocks fell for a second day on Wednesday and rates hit new highs as the Federal Reserve gave more guidance on how quickly it will tighten monetary policy to fight inflation, raising fears of a downturn in the economy. The Dow Jones Industrial Average fell 335 points, or about 1%. The S&P 500 slid 1.5% and the Nasdaq Composite fell 2.7% after losing about 2.3% on Tuesday. The Fed’s release of the…

View On WordPress

[marketresearchreportsnews-blog]

Hyperlipidemia Drugs Market Likely To Reach A Valuation Of Around USD 22.6 Billion By 2022 | Key Industry participants AstraZeneca, Merck & Co.

Hyperlipidemia Drugs Market Likely To Reach A Valuation Of Around USD 22.6 Billion By 2022 | Key Industry participants AstraZeneca, Merck & Co.

San Francisco, 21 September 2018 , The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, according to a new report by Grand View Research, Inc., expanding at a CAGR of 2.3% during the forecast period. Several factors, such as increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia,…

View On WordPress

[lightgardians]

CNBC's Meg Tirrell reports on what's driving the biotech sector to a possible breakout. The “Fast Money” traders weigh in.

[marketexclusive]

AMGEN INC. (NASDAQ:AMGN) Files An 8-K Entry into a Material Definitive Agreement

AMGEN INC. (NASDAQ:AMGN) Files An 8-K Entry into a Material Definitive Agreement

AMGEN INC. (NASDAQ:AMGN) Files An 8-K Entry into a Material Definitive AgreementItem 1.01. Entry into a Material Definitive Agreement. On January 6, 2017, Amgen Inc. (the “Company”) and Amgen USA Inc., a wholly owned subsidiary of the Company (“Amgen USA”), entered into a six-year Sourcing and Supply Agreement (the “New Agreement”) with DaVita Inc. (“DaVita”) to which Amgen USA will supply,…

View On WordPress

[geldhoch2]

Chad Morganlander of Stifel’s Washington Crossing Advisors advocates buying companies where dividends are increasing. “When the global economy—and particularly [that of the] United States—is growing slowly, people are looking for consistency and quality in individual companies,” said Morganlander, who manages a rising dividend-based portfolio. Companies with growing dividends generally have solid fundamentals, he claims.

[bloggingfordogs]

The market has been volatile as the Federal Reserve winds down its easy money policies. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 14 percentage points between June 25th and the end of October. SEC filings […]

[stockmarketsdaily]

New Post has been published on Stock Markets Daily

New Post has been published on http://www.stockmarketsdaily.com/fundamental-value-analysis-amgen-nasdaqamgn/17045/

Fundamental Value Analysis: Amgen (NASDAQ:AMGN)

(adsbygoogle = window.adsbygoogle || []).push();

We look at Amgen Inc. (NASDAQ:AMGN) [Trend Analysis] a company in the Healthcare industry currently at the attention of investors, to assess if it provides value for investors considering buying or selling it. Currently Amgen Inc. is trading at $151.31 after moving down -0.66% in the previous day of trading.

AMGN is trading with a trailing 12 month P/E multiple of 20.42 and an estimated forward P/E multiple of 14.33. The stock has an estimated 5 year annual growth of 11.16% and a PEG multiple of 1.83.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if Amgen Inc. is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of AMGN. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of AMGN being 1.83, we consider Amgen Inc. to likely be priced at fair value.

This analysis means that value buyers who do not currently hold Amgen Inc. (NASDAQ:AMGN) should probably look for better value alternatives and investors currently holding the stock should either continue to hold or sell and look for alternatives.

The mean analyst 12 month target price for Amgen Inc. (NASDAQ:AMGN) is currently $179.47 or 18.61% above the current price. Additionally, the stock has been as high as $173.60 and as low as $114.93 in the last 52 weeks. Analysts are estimating that AMGN will report earnings per share of $2.33 next quarter.